PBLS (Parabilis Medicines) PEG Ratio: N/A (As of Jul. 25, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PBLS Parabilis Medicines Inc PBLS
10 GF Score
Price $31.50
! 1 Warning Sign
View Full Analysis

What is Parabilis Medicines PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Parabilis Medicines's PE Ratio without NRI is . Parabilis Medicines's 5-Year EBITDA growth rate is 0.00%. Therefore, Parabilis Medicines's PEG Ratio for today is N/A.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for Parabilis Medicines's PEG Ratio or its related term are showing as below:



PBLS's PEG Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.85
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.

Parabilis Medicines  (NAS:PBLS) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.

Parabilis Medicines PEG Ratio Related Terms

Parabilis Medicines PEG Ratio Historical Data

* Premium members only.

The historical data trend for Parabilis Medicines's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Parabilis Medicines PEG Ratio Chart

Parabilis Medicines Annual Data
Trend Dec24 Dec25
PEG Ratio
0.00 0.00

Parabilis Medicines Semi-Annual Data
Dec24 Dec25
PEG Ratio 0.00 0.00

PBLS vs IDYA, ELVN, BEAM: PEG Ratio Comparison

For the Biotechnology subindustry, Parabilis Medicines's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Parabilis Medicines PEG Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Parabilis Medicines's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Parabilis Medicines's PEG Ratio falls into.


PBLS
10GF Score
Parabilis Medicines Inc PBLS
PEG Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Parabilis Medicines PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Parabilis Medicines's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=/0.00
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

Parabilis Medicines Business Description

Address 30 Acorn Park Drive, Cambridge Discovery Park, Cambridge, MA, USA, 02140
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between ?-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/?-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.
10GF Score

Get the complete analysis for PBLS

PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$31.50
Price